Trevi Therapeutics (TRVI) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.04B and a free-cash-flow yield of -2.2%. Nama's AI scorecard rates it Sell, 3.2 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Sell · 3.2/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Middle · +19.3% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-29.1%
How far the last close sits under the highest price of the past five years.
Market cap
$2.04B
Trailing P/E
—
Price / book
6.3
Price / sales
—
FCF yield
-2.2%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
1.0
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
TRVI earnings
Next report: Nov 12, 2026 (Q3 2026, EPS estimate -$0.13).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 6, 2026
-$0.11
-$0.11
+0.0%
$0
Q1 2026
May 5, 2026
-$0.09
-$0.07
-28.6%
$0
Q4 2025
Mar 17, 2026
-$0.06
-$0.10
+40.0%
$0
Q3 2025
Nov 13, 2025
-$0.08
-$0.10
+20.0%
$0
TRVI analyst price target
Median target $25.00 from 11 analysts, ranging $23.00 – $40.00.
Nama's AI scorecard currently rates Trevi Therapeutics Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does TRVI report earnings?
Trevi Therapeutics's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$0.13.
What is the TRVI price target?
The median analyst price target from 11 analysts is $25.00, with a range of $23.00 – $40.00.
Is TRVI Shariah compliant?
Nama's AAOIFI-style screen reads Trevi Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.